InnoCare Pharma (SHA:688428, HKG:9969) booked an attributable net profit of 246.4 million yuan in the first half of 2026, returning from a loss of 30.1 million yuan a year ago.
Earnings per share stood at 0.14 yuan per share, compared with loss per share of 0.02 yuan per share, according to a Hong Kong bourse disclosure on Monday.
The pharmaceutical company's revenue jumped 55.5% to 1.14 billion yuan from 731.4 million yuan a year earlier.